echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Genome editing on blood vessel wall cells for the first time

    Genome editing on blood vessel wall cells for the first time

    • Last Update: 2022-01-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The laboratory of Dr.


    "The nanoparticle we developed is a powerful new delivery system for genome editing of vascular endothelial cells, which can be used to treat many diseases, including acute respiratory distress syndrome caused by severe COVID-19," senior author of Lurie Children Dr.


    Endothelial dysfunction is the root cause of many diseases, such as coronary artery disease, stroke, bronchopulmonary dysplasia and pulmonary hypertension


    At this stage, Dr.


    "Our nanoparticle delivery system for genome editing and transgene expression is also a huge advancement in cardiovascular research," Dr.




    Magazine

    Cell Reports

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.